The clinical study on the functional cure of PD-L1 antibody ASC22 hepatitis B was selected as the "Best Abstract of the Conference" by the Review Committee of the American Association for the Study of Liver Diseases

-Being included in the "Best Abstract of the Conference" is an honor, which shows that the AASLD Review Committee has given a high evaluation of Gerry's research in the field of chronic hepatitis B

-Phase IIb study showed that among patients with baseline hepatitis B surface antigen ≤ 500 IU/mL, 19% of patients in the treatment group continued to disappear hepatitis B surface antigen, while no patients in the placebo group achieved hepatitis B surface antigen disappearance

Hangzhou and Shaoxing, China, November 16, 2021/PRNewswire/ - Golly Pharmaceutical Co.

The focus of Phase IIa and Phase IIb studies is the use of subcutaneous injection of PD-L1 antibody ASC22 (Envolimab) to achieve functional cure of chronic hepatitis B (CHB)

The titles of these two clinical studies are: (1) subcutaneous injection of PD-L1 antibody ASC22 (envolimab) for the treatment of patients with chronic hepatitis B in a phase IIa trial; and (2) subcutaneous injection of PD-L1 antibody ASC22 (envolimab) Wollimumab) combined with nucleoside (acid) analog therapy to achieve the disappearance of hepatitis B surface antigen in patients with chronic hepatitis B: Interim results of phase IIb clinical trials

"It is a great honor that both Phase IIa and Phase IIb studies were selected as the'Best Abstract of the Conference', indicating that the AASLD Review Committee affirmed our high-quality research and the significant unmet medical needs in the field of functional hepatitis B healing," Ge Li Founder, Chairman of the Board and CEO Dr.

About songli

Gale is an innovative R&D-driven biotechnology company listed on the Hong Kong Stock Exchange (1672.

1.

2.

3.

4.

Source: Golly Pharmaceutical Co.